jimnyc
02-26-2021, 08:18 PM
BUT...
and it's definitely something to keep in mind.
Now, both the Pfizer and Moderna shots require 2 shots separated by nearly 30 days. And now, they are saying that even just one of those shots is about 92% effective. And then they only go up to like 94 and 95% effective - which overall is fantastic, and my preference would be one of these 2. Sucks to have to wait and go visit the doc twice, but that's one hell of an effective vaccine. Variants of the yearly flu and the vaccine are usually in the 40-60+% effective.
Now Johnson and Johnson are about to come out on the same emergency use authorization.
Fantastic to have another to the addition, and hopefully means more vaccinated and quicker. AND with this shot there will only be a need for one shot. But the others being mid-90% effective, and this one approximately 66-72% effective, that's a drop in 20-25%. And they may very well be likely to push out and into your arm whichever is available. And this one being so much easier to be stored, it's a good possibility...
--
US closer to its 3rd COVID vaccine — and this one only needs one shot. What to know
The U.S. Food and Drug Administration released a report on Wednesday that says the one-dose Johnson & Johnson COVID-19 vaccine has a “favorable safety profile with no specific safety concerns,” clearing the way for emergency use authorization.
A committee of scientific experts will meet on Friday to discuss the vaccine’s safety and efficacy, as it did for the authorized Pfizer-BioNTech and Moderna shots. If the group decides to recommend the Johnson & Johnson vaccine for FDA authorization, the shot will become the nation’s third COVID-19 vaccine, joining the fight against the pandemic spurred by more contagious variants.
The vaccine requires one dose and can be stored for three months at normal temperatures, easing distribution efforts and accelerating vaccination rates compared to the two-dose Pfizer and Moderna shots that require ultra cold refrigeration, which some regions lack access to.
Dr. Paul Stoffels, chief scientific officer for Johnson & Johnson, said in January that the results “represent a promising moment.”
“The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response.”
The Phase 3 clinical trial, which included nearly 44,000 participants 18 years and older, found that the Johnson & Johnson vaccine was overall 66% effective at preventing moderate to severe COVID-19 in the lab at least 28 days after getting jabbed.
In the U.S., the vaccine was about 72% effective at preventing moderate to severe COVID-19. However, that percentage dropped to 64% in South Africa, where a more contagious coronavirus variant has dominated all others. Still, the vaccine offered “similarly high” protection in both regions, including Brazil, where another more transmissible variant has emerged.
Both the Pfizer and Moderna vaccines have efficacy rates of about 95%.
Rest - https://news.yahoo.com/us-closer-3rd-covid-vaccine-170209906.html
and it's definitely something to keep in mind.
Now, both the Pfizer and Moderna shots require 2 shots separated by nearly 30 days. And now, they are saying that even just one of those shots is about 92% effective. And then they only go up to like 94 and 95% effective - which overall is fantastic, and my preference would be one of these 2. Sucks to have to wait and go visit the doc twice, but that's one hell of an effective vaccine. Variants of the yearly flu and the vaccine are usually in the 40-60+% effective.
Now Johnson and Johnson are about to come out on the same emergency use authorization.
Fantastic to have another to the addition, and hopefully means more vaccinated and quicker. AND with this shot there will only be a need for one shot. But the others being mid-90% effective, and this one approximately 66-72% effective, that's a drop in 20-25%. And they may very well be likely to push out and into your arm whichever is available. And this one being so much easier to be stored, it's a good possibility...
--
US closer to its 3rd COVID vaccine — and this one only needs one shot. What to know
The U.S. Food and Drug Administration released a report on Wednesday that says the one-dose Johnson & Johnson COVID-19 vaccine has a “favorable safety profile with no specific safety concerns,” clearing the way for emergency use authorization.
A committee of scientific experts will meet on Friday to discuss the vaccine’s safety and efficacy, as it did for the authorized Pfizer-BioNTech and Moderna shots. If the group decides to recommend the Johnson & Johnson vaccine for FDA authorization, the shot will become the nation’s third COVID-19 vaccine, joining the fight against the pandemic spurred by more contagious variants.
The vaccine requires one dose and can be stored for three months at normal temperatures, easing distribution efforts and accelerating vaccination rates compared to the two-dose Pfizer and Moderna shots that require ultra cold refrigeration, which some regions lack access to.
Dr. Paul Stoffels, chief scientific officer for Johnson & Johnson, said in January that the results “represent a promising moment.”
“The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response.”
The Phase 3 clinical trial, which included nearly 44,000 participants 18 years and older, found that the Johnson & Johnson vaccine was overall 66% effective at preventing moderate to severe COVID-19 in the lab at least 28 days after getting jabbed.
In the U.S., the vaccine was about 72% effective at preventing moderate to severe COVID-19. However, that percentage dropped to 64% in South Africa, where a more contagious coronavirus variant has dominated all others. Still, the vaccine offered “similarly high” protection in both regions, including Brazil, where another more transmissible variant has emerged.
Both the Pfizer and Moderna vaccines have efficacy rates of about 95%.
Rest - https://news.yahoo.com/us-closer-3rd-covid-vaccine-170209906.html